Isomerase Therapeutics

Executive Summary

Isomerase Therapeutics is a UK-based synthetic biology company founded in 2013, specializing in biocatalysis, enzyme engineering, and microbial strain development to produce novel small molecule therapeutics and industrial enzymes. The company operates as an innovation partner, offering end-to-end platform services and research collaborations to pharmaceutical and industrial partners. By leveraging sustainable fermentation and enzymatic processes, Isomerase enables the scalable production of complex molecules that are difficult to synthesize chemically. Despite being privately held with limited public financial data, the company’s platform approach has potential applications in drug discovery, green chemistry, and specialty chemicals.

Upcoming Catalysts (preview)

• Q4 2026Announcement of first major pharmaceutical partnership60% success
• Q2 2026Validation of enzyme engineering platform through peer-reviewed publication or new patent70% success
• Q3 2026Series A or B funding round closure50% success